|Bid||77.25 x 800|
|Ask||77.26 x 1400|
|Day's range||77.15 - 78.76|
|52-week range||68.44 - 84.56|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||35.15|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||2.60 (3.32%)|
|Ex-dividend date||14 Sep 2021|
|1y target est||94.08|
Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.
These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics have already made a big splash with positive results for their COVID-19 pill. However, there are are other companies nipping at their heels. In this Motley Fool Live video recorded on Oct.